Sipeimine

• Description:

  Sipeimine (Imperialine) is an inhibitor targeting the PI3K/AKT/NF-κB pathway and NLRP3 inflammasome, which can competitively bind to PI3K and p65. Sipeimine inhibits PI3K/AKT phosphorylation, blocks NF-κB nuclear translocation and NLRP3 inflammasome activation. Sipeimine exerts anti-inflammatory activities, inhibits pyroptosis and ferroptosis, and protects the extracellular matrix. Sipeimine can reduce cartilage degradation and synovial inflammation in osteoarthritis and improve PM2.5-induced lung injury. Sipeimine is mainly used in the study of anti-inflammatory and degenerative diseases[1][2].

• Product Name Alternative:

  Imperialine

• UNSPSC:

  12352005

• Hazard Statement:

  H302+H312+H332

• Target:

  Akt; Ferroptosis; NF-κB; NOD-like Receptor (NLR) ; PI3K; Pyroptosis

• Type:

  Natural Products

• Related Pathways:

  Apoptosis; Immunology/Inflammation; NF-κB; PI3K/Akt/mTOR

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Sipeimine.html

• Concentration:

  10mM

• Purity:

  98.57

• Solubility:

  DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  C[C@@]([C@@]1([H])C2=O)(CC[C@H](O)C1)[C@]3([H])[C@](C2)([H])[C@@](CC[C@]4([H])[C@@]5([H])CN(C[C@@H](C)CC6)[C@]6([H])[C@]4(O)C)([H])[C@@]5([H])C3

• Molecular Formula:

  C27H43NO3

• Molecular Weight:

  429.64

• Precautions:

  H302+H312+H332

• References & Citations:

  [1]Fang Y, et al. Sipeimine ameliorates osteoarthritis progression by suppression of NLRP3 inflammasome-mediated pyroptosis through inhibition of PI3K/AKT/NF-κB pathway: An in vitro and in vivo study. J Orthop Translat. 2024 May 9;46:1-17.|[2]Wang Y, et al. Sipeimine ameliorates PM2.5-induced lung injury by inhibiting ferroptosis via the PI3K/Akt/Nrf2 pathway: A network pharmacology approach. Ecotoxicol Environ Saf. 2022 Jul 1;239:113615.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  No Development Reported

• CAS Number:

  61825-98-7